{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04649385",
            "orgStudyIdInfo": {
                "id": "BGB-A317-15025-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "CTR20212721",
                    "type": "OTHER",
                    "domain": "ChinaDrugTrials"
                }
            ],
            "organization": {
                "fullName": "BeiGene",
                "class": "INDUSTRY"
            },
            "briefTitle": "BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "bgb-alone-and-in-combination-with-anti-pd-monoclonal-antibody-tislelizumab-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-03-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-11-25",
            "studyFirstSubmitQcDate": "2020-11-25",
            "studyFirstPostDateStruct": {
                "date": "2020-12-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BeiGene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 330,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1a: Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses\n\nPart B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy )",
                    "interventionNames": [
                        "Drug: BGB-15025",
                        "Drug: Tislelizumab"
                    ]
                },
                {
                    "label": "Phase 1b: Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Phase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a",
                    "interventionNames": [
                        "Drug: BGB-15025",
                        "Drug: Tislelizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BGB-15025",
                    "description": "Administered orally once or twice daily (QD or BID)",
                    "armGroupLabels": [
                        "Phase 1a: Dose Escalation",
                        "Phase 1b: Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tislelizumab",
                    "description": "Administered 200 mg intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Phase 1a: Dose Escalation",
                        "Phase 1b: Dose Expansion"
                    ],
                    "otherNames": [
                        "BGB-A317"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1a: Number of participants with dose limiting toxicities (DLTs)",
                    "description": "Participants will be considered evaluable for DLTs if they 1) received \u2265 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.",
                    "timeFrame": "Up to 3 Years"
                },
                {
                    "measure": "Phase 1a: Number of Participants Experiencing Adverse Events (AEs)",
                    "timeFrame": "Up to 4 Years"
                },
                {
                    "measure": "Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)",
                    "timeFrame": "Up to 4 years"
                },
                {
                    "measure": "The maximum tolerated dose (MTD) of BGB-15025",
                    "description": "The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%",
                    "timeFrame": "Up to 3 Years"
                },
                {
                    "measure": "Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapy",
                    "description": "The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "RDFE of BGB-15025 in combination with tislelizumab",
                    "description": "The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Phase 1b: Overall Response Rate (ORR) as assessed by the investigator",
                    "timeFrame": "Up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1a: Overall Response Rate (ORR) as assessed by the investigator",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Duration Of Response (DOR) as assessed by the investigator",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Disease Control Rate (DCR) as assessed by the investigator",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Minimum observed plasma concentration (Cmin) of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Time to maximum plasma concentration (Tmax) of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Half-life of (t1/2) of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Area under the concentration-time curve (AUC) of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Apparent clearance (CL/F) of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Apparent volume of distribution (Vz/F) of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Accumulation Ratio for Cmax of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Accumulation Ratio for AUC of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1a: Metabolite to parent ratio for BGB-15025 and its metabolite",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1b: Number of Participants Experiencing Adverse Events (AEs)",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs)",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Phase 1b: Plasma Concentrations of BGB-15025",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1b: Plasma Concentrations of the metabolite",
                    "timeFrame": "Predose up to 8 hours postdose"
                },
                {
                    "measure": "Phase 1b: Number of participants with dose limiting toxicities (DLTs)",
                    "description": "Participants will be considered evaluable for DLTs if they 1) received \u2265 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.",
                    "timeFrame": "Up to 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Phase 1a (dose escalation): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available, not tolerated or refused, and who have not received prior therapy targeting HPK1\n2. Phase 1b (dose expansion): Participant with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors, including non-small cell lung cancer, esophageal cancer or gastric/Gastroesophageal junction cancer (other solid tumors may be included) who have progressed following systemic anticancer therapies or have no prior systemic treatment for advanced disease\n3. At least 1 measurable lesion as defined per RECIST 1.1.\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1\n5. Adequate organ function as indicated by the following laboratory values up to first dose of study treatment: Hemoglobin\u2265 90 g/L, Absolute neutrophil count \u2265 1.5 x 109/L , Serum total bilirubin \u2264 1.5 x ULN (\\< 3 x ULN for participants with Gilbert syndrome ), AST and ALT\u2264 2.5 x ULN\n\nKey Exclusion Criteria:\n\n1. Active leptomeningeal disease or uncontrolled and untreated brain metastasis.\n2. Active autoimmune diseases or history of autoimmune diseases that may relapse\n3. Any active malignancy \u2264 2 years before the first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent\n4. Any condition that required systemic treatment with either corticosteroids (\\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication \u2264 14 days before the first dose of study treatment\n5. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BeiGene",
                    "role": "CONTACT",
                    "phone": "+1-877-828-5568",
                    "email": "clinicaltrials@beigene.com"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Texas Md Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030-4009",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Ut Health San Antonio Mays Cancer Center",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Prince of Wales Hospital",
                    "status": "RECRUITING",
                    "city": "Randwick",
                    "state": "New South Wales",
                    "zip": "2031",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.91439,
                        "lon": 151.24895
                    }
                },
                {
                    "facility": "One Clinical Research",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "Harbin Medical University Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Harbin",
                    "state": "Heilongjiang",
                    "zip": "150000",
                    "country": "China",
                    "geoPoint": {
                        "lat": 45.75,
                        "lon": 126.65
                    }
                },
                {
                    "facility": "Henan Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Zhengzhou",
                    "state": "Henan",
                    "zip": "450000",
                    "country": "China",
                    "geoPoint": {
                        "lat": 34.75778,
                        "lon": 113.64861
                    }
                },
                {
                    "facility": "The First Affiliated Hospital of Zhengzhou University",
                    "status": "RECRUITING",
                    "city": "Zhengzhou",
                    "state": "Henan",
                    "zip": "450052",
                    "country": "China",
                    "geoPoint": {
                        "lat": 34.75778,
                        "lon": 113.64861
                    }
                },
                {
                    "facility": "Shanghai Pulmonary Hospital",
                    "status": "RECRUITING",
                    "city": "Shanghai",
                    "state": "Shanghai",
                    "zip": "200433",
                    "country": "China",
                    "geoPoint": {
                        "lat": 31.22222,
                        "lon": 121.45806
                    }
                },
                {
                    "facility": "West China Hospital, Sichuan University",
                    "status": "RECRUITING",
                    "city": "Chengdu",
                    "state": "Sichuan",
                    "zip": "610041",
                    "country": "China",
                    "geoPoint": {
                        "lat": 30.66667,
                        "lon": 104.06667
                    }
                },
                {
                    "facility": "Tianjin Medical University Cancer Institute and Hospital",
                    "status": "RECRUITING",
                    "city": "Tianjin",
                    "state": "Tianjin",
                    "zip": "300060",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.14222,
                        "lon": 117.17667
                    }
                },
                {
                    "facility": "Sir Run Run Shaw Hospital, Zhejiang University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Hangzhou",
                    "state": "Zhejiang",
                    "zip": "310016",
                    "country": "China",
                    "geoPoint": {
                        "lat": 30.29365,
                        "lon": 120.16142
                    }
                },
                {
                    "facility": "Seoul National University Bundang Hospital",
                    "status": "RECRUITING",
                    "city": "Seongnamsi",
                    "state": "Gyeonggido",
                    "zip": "13620",
                    "country": "Korea, Republic of"
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital Yonsei University Health System",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "The Catholic University of Korea, Seoul St Marys Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "06591",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Auckland City Hospital",
                    "status": "RECRUITING",
                    "city": "Auckland",
                    "zip": "1023",
                    "country": "New Zealand",
                    "geoPoint": {
                        "lat": -36.84853,
                        "lon": 174.76349
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000707970",
                    "term": "Tislelizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M137899",
                    "name": "Tislelizumab",
                    "asFound": "Nerve block",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}